(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.15%) $0.928
(0.13%) $10.86
(0.01%) $0.792
(-0.07%) $92.51
@ $11.35
Issued: 14 Feb 2024 @ 09:30
Return: 38.85%
Previous signal: Feb 13 - 09:30
Previous signal:
Return: 3.37 %
Live Chart Being Loaded With Signals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers...
Stats | |
---|---|
Today's Volume | 579 811 |
Average Volume | 823 732 |
Market Cap | 1.12B |
EPS | $0 ( 2024-03-06 ) |
Next earnings date | ( $-0.850 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.53 |
ATR14 | $0.0210 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-12 | Epperly Melissa B, | Sell | 2 573 | Common Stock |
2024-02-12 | Gallagher Cam | Sell | 1 173 | Common Stock |
2024-02-01 | Hausman Diana | Buy | 337 500 | Common Stock |
2024-02-01 | Hausman Diana | Buy | 337 500 | Stock Option (Right to Buy) |
2024-02-01 | Lackner Mark | Buy | 141 000 | Common Stock |
INSIDER POWER |
---|
87.25 |
Last 96 transactions |
Buy: 10 141 496 | Sell: 672 173 |
Volume Correlation
Zentalis Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations | |
---|---|
RAVN | -0.813 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Zentalis Pharmaceuticals Correlation - Currency/Commodity
Zentalis Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-337 000 (0.00 %) |
EPS: | $-0.860 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-348 000 (0.00 %) |
EPS: | $-0.790 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-344 000 (0.00 %) |
EPS: | $-1.850 |
Financial Reports:
No articles found.
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators